Halaven is a Intravenous Injection in the Human Prescription Drug category. It is labeled and distributed by Bsp Pharmaceuticals Spa. The primary component is Eribulin Mesylate.
| Product ID | 43624-002_011afacd-c29f-4808-b38f-f113c1bb2717 |
| NDC | 43624-002 |
| Product Type | Human Prescription Drug |
| Proprietary Name | Halaven |
| Generic Name | Eribulin Mesylate |
| Dosage Form | Injection |
| Route of Administration | INTRAVENOUS |
| Marketing Start Date | 2017-04-21 |
| Marketing Category | NDA / NDA |
| Application Number | NDA201532 |
| Labeler Name | BSP Pharmaceuticals SpA |
| Substance Name | ERIBULIN MESYLATE |
| Active Ingredient Strength | 1 mg/mL |
| Pharm Classes | Microtubule Inhibition [PE],Microtubule Inhibitor [EPC] |
| NDC Exclude Flag | N |
| Listing Certified Through | 2021-12-31 |
| Marketing Start Date | 2017-04-21 |
| NDC Exclude Flag | N |
| Sample Package? | N |
| Marketing Category | NDA |
| Application Number | NDA201532 |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Marketing Start Date | 2017-04-21 |
| Ingredient | Strength |
|---|---|
| ERIBULIN MESYLATE | .5 mg/mL |
| SPL SET ID: | 8fc8fe1d-59fe-4e43-a95c-e7aa13422cd6 |
| Manufacturer | |
| UNII | |
| RxNorm Concept Unique ID - RxCUI |
| NDC | Brand Name | Generic Name |
|---|---|---|
| 43624-002 | Halaven | eribulin mesylate |
| 62856-389 | Halaven | eribulin mesylate |
Mark Image Registration | Serial | Company Trademark Application Date |
|---|---|
![]() HALAVEN 77886054 not registered Dead/Abandoned |
Eisai R&D Management Co., Ltd. 2009-12-04 |
![]() HALAVEN 77097283 3962019 Live/Registered |
Eisai R&D Management Co., Ltd. 2007-02-01 |